期刊文献+

探讨沙格列汀联合阿法骨化醇对T2DM合并骨代谢疾病患者血清25(OH)D_(3)水平、血糖指标与骨代谢指标的影响

Effects of Combination Therapy with Saxagliptin and Alfacalcidol on Serum 25(OH)D_(3)Levels,Blood Glucose and Bone Metabolism Markers in Patients with T2DM Complicated with Bone Metabolic Diseases
下载PDF
导出
摘要 目的探讨沙格列汀联合阿法骨化醇对2型糖尿病(type 2 diabetes mellitus,T2DM)合并骨代谢疾病患者血清25-羟基维生素D_(3)[serum 25-hydroxyvitamin D_(3),25(OH)D_(3)]水平及血糖指标与骨代谢指标的影响。方法选取2021年1月—2022年12月枣庄市山亭区人民医院收治的120例T2DM合并骨代谢疾病患者为研究对象,按照不同治疗方法分为观察组(n=60)和对照组(n=60)。对照组采用二甲双胍联合阿法骨化醇治疗,观察组采用沙格列汀联合阿法骨化醇治疗,对比两组胰岛素指标、血清25(OH)D_(3)水平、骨代谢指标和糖脂代谢指标。结果治疗后,观察组空腹胰岛素水平、胰岛素抵抗指数、Ⅰ型胶原羧基端肽β特殊序列、空腹血糖、餐后2 h血糖、糖化血红蛋白、总胆固醇、甘油三酯水平均低于对照组,血清25(OH)D_(3)、总Ⅰ型前胶原氨基端延长肽、骨钙素水平高于对照组,差异有统计学意义(P均<0.05)。结论沙格列汀与阿法骨化醇联合疗法为T2DM患者提供一种多靶点治疗策略,疗效显著,不仅改善血糖水平,降低胰岛素抵抗,还能兼顾骨健康。 Objective To investigate the effects of saxagliptin combined with alfacalcidol on serum 25-hydroxyvita-min D_(3)[25(OH)D_(3)]level,blood glucose index and bone metabolism index in patients with type 2 diabetes mellitus(T2DM)complicated with bone metabolic diseases.Methods A total of 120 patients with T2DM complicated with bone metabolic diseases admitted to Shanting District People's Hospital of Zaozhuang from January 2021 to December 2022 were selected as the research objects.According to different treatment methods,they were divided into observa-tion group(n=60)and control group(n=60).The control group was treated with metformin combined with alfacalcidol,and the observation group was treated with saxagliptin combined with alfacalcidol.The insulin indexes,serum 25(OH)D_(3)level,bone metabolism indexes and glucose and lipid metabolism indexes were compared between the two groups.Results The levels of fasting insulin,insulin resistance index,type I collagen carboxy terminal peptideβspecial se-quence,fasting plasma glucose,2-hour postprandial plasma glucose,glycated hemoglobin A1c,total cholesterol and triglyceride in the observation group were lower than those in the control group,and the levels of 25(OH)D_(3),total type I procollagen aminoter-minal elongation peptide,osteocalcin was higher than that in the control group,and the differ-ences were statistically significant(all P<0.05).Conclusion The combination therapy of saxagliptin and alfacalcidol provides a multi-target treatment strategy for T2DM patients,and the curative effect is very significant.It not only im-proves blood glucose levels,reduces insulin resistance,but also takes into account bone health.
作者 巩菲菲 孙法凤 张厚慈 GONG Feifei;SUN Fafeng;ZHANG Houci(Department of Endocrinology,Shanting District People's Hospital of Zaozhuang,Zaozhuang 277500,Shandong,China;Department of Neurology,Shanting District People's Hospital of Zaozhuang,Zaozhuang 277500,Shandong,China)
出处 《糖尿病新世界》 2024年第16期80-83,共4页 Diabetes New World
关键词 沙格列汀 阿法骨化醇 2型糖尿病 血清25(OH)D_(3) 骨代谢 Saxagliptin Alfacalcitol Type 2 diabetes Serum 25(OH)D_(3) Bone metabolism
  • 相关文献

参考文献12

二级参考文献132

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部